Abuse-Deterrent Soft Capsule Matrix for Opioid Extraction Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for abuse deterrent pharmaceutical compositions that prevent the extraction and misuse of prescription medications, particularly opioids, by resisting tampering and rapid release under boiling conditions.
Innovation Solution
The development of a tamper-resistant controlled release matrix comprising a combination of lipid or lipophilic vehicles, organogelators, hydrophilic polymers, and antioxidants, encapsulated in a soft capsule shell, which resists crushing, grinding, and solvation, and slows the release of active pharmaceutical ingredients under boiling conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a traditional pharmaceutical formulation is used, then the active pharmaceutical ingredient is readily extracted and absorbed, but the formulation is susceptible to abuse and tampering
Solution Approach 1:
The patent employs a composite matrix formulation integrating multiple components: a hydrophilic polymer matrix (e.g., HPMC, carbomer) providing structural framework, lipid vehicles (e.g., glyceryl monostearate, polyethylene glycol glyceride esters) for drug solubility and controlled release, and plasticizers (e.g., glycerol, polyethylene glycol) for flexibility. This composite structure resists extraction by both aqueous and organic solvents while maintaining manufacturability through established hot-melt extrusion and molding techniques
Solution Approach 2:
The patent modifies formulation parameters including the glass transition temperature (Tg) of the matrix by selecting polymers with appropriate Tg values (e.g., HPMC with Tg of 80-100°C), adjusting the ratio of hydrophilic to lipophilic components, and controlling the molecular weight and viscosity of polymer materials. These parameter changes optimize the matrix's resistance to extraction while ensuring the formulation remains processable during manufacturing
2Reliability
If the active pharmaceutical ingredient is released rapidly, then the therapeutic effect is immediate, but the formulation is prone to dose dumping and abuse
Solution Approach 1:
The patent utilizes a porous hydrophilic polymer matrix that allows controlled water penetration and drug diffusion. The matrix structure contains interconnected pores formed during manufacturing that enable gradual drug release through diffusion and erosion mechanisms. The pore size and distribution are controlled by formulation parameters, providing sustained release over 12-24 hours while preventing rapid dose dumping even when exposed to boiling conditions or organic solvents
Solution Approach 2:
The patent employs a dynamic release mechanism where the matrix progressively erodes and swells over time in the gastrointestinal tract. The hydrophilic polymer matrix absorbs water, swells to form a gel layer, and gradually erodes to release the drug. This dynamic process ensures controlled release kinetics that adapt to physiological conditions while resisting extraction by digestive enzymes and gastric acid, preventing both premature release and abuse
3Reliability
If the formulation is made resistant to tampering, then the likelihood of abuse is reduced, but the manufacturing process becomes more complex
Solution Approach 1:
The patent employs a flexible gel matrix formed by hydrophilic polymers that creates a cohesive, tamper-resistant structure. The matrix forms a continuous gel network that resists mechanical manipulation such as crushing, grinding, or cutting. When subjected to physical stress, the gel matrix deforms elastically and maintains structural integrity, preventing the release of active pharmaceutical ingredient. The flexibility of the gel allows the matrix to accommodate physiological conditions in the gastrointestinal tract while maintaining resistance to external tampering attempts
4Reliability
If the formulation uses multiple components for abuse deterrence, then the protection against extraction is improved, but the number of ingredients and regulatory requirements increases
Solution Approach 1:
The patent employs multi-functional components that perform multiple roles within the formulation. For example, the hydrophilic polymer matrix serves simultaneously as the structural framework, the controlled release mechanism, and the tamper-resistant barrier. The lipid vehicles provide both drug solubility enhancement and extraction resistance. The plasticizers contribute to both matrix flexibility and resistance to mechanical tampering. This multi-functionality reduces the need for separate additive components while achieving comprehensive abuse deterrence
Solution Approach 2:
The patent combines multiple protective functions into integrated matrix components rather than using separate additive systems. The hydrophilic polymer matrix is formulated to simultaneously provide controlled release kinetics, resistance to aqueous extraction, and mechanical tamper resistance. The lipid-polymer composite structure merges the benefits of both hydrophilic and lipophilic phases to create a matrix that resists both water-based and organic solvent extraction. This merging of functions into fewer components simplifies the overall formulation while maintaining robust abuse deterrence properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively minimizes the likelihood of misuse by preventing rapid extraction and release of active ingredients, providing controlled release properties that reduce the risk of abuse and minimize opioid-induced bowel dysfunction.
Implementation Method 1
The development of a tamper-resistant controlled release matrix comprising a combination of lipid or lipophilic vehicles, organogelators, hydrophilic polymers, and antioxidants
Implementation Method 2
The matrix formulations described herein minimize the likelihood of tampering, 'dose dumping,' or the extraction of active pharmaceutical ingredients from the composition
Data Source
AI summary
Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.